Samuel D Rabkin

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 20

Top Venues

Journal for immunotherapy of cancer

Oncoimmunology

Nature communications

Nature cancer

Massachusetts General Hospital and Harvard Medical School

University of Chicago (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Massachusetts General Hospital and Harvard Medical School

United States

Professor :: Neurosurgery

Georgetown University Medical Center

United States

Assistant Professor :: Departments of Neurosurgery and Microbiology & Immunology

Memorial Sloan-Kettering Cancer Center

United States

Assistant Member :: Molecular Biology

Education History

University of Chicago

United States

PHD :: Microbiology

Hebrew University of Jerusalem

Israel

MSC :: Microbiology

University of Toronto

Canada

BSC

Publications

Hongbin Wang, Mia Borlongan, Howard L Kaufman, Uyen Le, Hans J Nauwynck, Samuel D Rabkin, Dipongkor Saha
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? Journal for immunotherapy of cancer 12 (5) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Hongbin Wang, Mia Borlongan, Howard L Kaufman, Uyen Le, Hans J Nauwynck, Samuel D Rabkin, Dipongkor Saha
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? Journal for immunotherapy of cancer 12 (5) (2024)
Hongbin Wang, Mia Borlongan, Howard L Kaufman, Uyen Le, Hans J Nauwynck, Samuel D Rabkin, Dipongkor Saha
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? Journal for immunotherapy of cancer 12 (5) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Judit Sanchez Gil, Samuel D Rabkin
An armed oncolytic virus for GBM Destruction. Nature cancer 3 (11) (2022)
Nusrat Jahan, Shanawaz M Ghouse, Robert L Martuza, Samuel D Rabkin
In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses 13 (9) (2021)
Ming Li, Guoping Li, Juri Kiyokawa, Zain Tirmizi, Leland G Richardson, Jianfang Ning, Saumya Das, Robert L Martuza, Anat Stemmer-Rachamimov, Samuel D Rabkin, Hiroaki Wakimoto
Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta neuropathologica communications 8 (1) (2020)
Juri Kiyokawa, Yoichiro Kawamura, Shanawaz M Ghouse, Simge Acar, Erinç Barçın, Jordi Martínez-Quintanilla, Robert L Martuza, Ramon Alemany, Samuel D Rabkin, Khalid Shah, Hiroaki Wakimoto
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (3) (2020)
Shunchuan Zhang, Samuel D Rabkin
The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Expert opinion on drug discovery 16 (4) (2020)
Ming-Ru Wu, Lior Nissim, Doron Stupp, Erez Pery, Adina Binder-Nissim, Karen Weisinger, Casper Enghuus, Sebastian R Palacios, Melissa Humphrey, Zhizhuo Zhang, Eva Maria Novoa, Manolis Kellis, Ron Weiss, Samuel D Rabkin, Yuval Tabach, Timothy K Lu
A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nature communications 10 (1) (2019)
Praveen K Bommareddy, Salvatore Aspromonte, Andrew Zloza, Samuel D Rabkin, Howard L Kaufman
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Science translational medicine 10 (471) (2019)
Praveen K Bommareddy, Samuel D Rabkin, Howard L Kaufman
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology 8 (4) (2019)
Jian-Fang Ning, Monica Stanciu, Melissa R Humphrey, Joshua Gorham, Hiroko Wakimoto, Reiko Nishihara, Jacqueline Lees, Lee Zou, Robert L Martuza, Hiroaki Wakimoto, Samuel D Rabkin
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nature communications 10 (1) (2019)
Praveen K Bommareddy, Andrew Zloza, Samuel D Rabkin, Howard L Kaufman
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology 8 (7) (2019)
Cole Peters, Max Paget, Kizito-Tshitoko Tshilenge, Dipongkor Saha, Slawomir Antoszczyk, Anouk Baars, Thomas Frost, Robert L Martuza, Hiroaki Wakimoto, Samuel D Rabkin
Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells. Journal of virology 92 (15) (2018)

Samuel D Rabkin.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Samuel D Rabkin